Sekio Nagayama
Overview
Explore the profile of Sekio Nagayama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okayama T, Yoshisue K, Kuwata K, Komuro M, Ohta S, Nagayama S
J Pharmacol Exp Ther
. 2011 Nov;
340(2):457-62.
PMID: 22076553
ααα-Trifluorothymidine (TFT), an anticancer nucleoside analog, is a potent thymidylate synthase inhibitor. TFT exerts its antitumor activity primarily by inducing DNA fragmentation after incorporation of the triphosphate form of TFT...
2.
Yamamiya I, Yoshisue K, Matsushima E, Nagayama S
Drug Metab Dispos
. 2010 May;
38(8):1267-76.
PMID: 20463005
Tegafur (FT) is a 5-fluorouracil (5-FU) prodrug that has been clinically used for various cancer chemotherapies. The following metabolites of FT were identified in patients: 5-FU, fluoro-beta-alanine, and gamma-butyrolactone (GBL)...
3.
Matsuoka-Kawano K, Yoshinari K, Nagayama S, Yamazoe Y
Chem Biol Interact
. 2010 Feb;
185(1):33-41.
PMID: 20171196
(Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (TSU-16), is a potent anti-angiogenic agent that inhibits the tyrosine kinase of vascular endothelial growth factor receptor-2. In clinical trials with daily or twice weekly intravenous administration of TSU-16,...
4.
Yoshisue K, Kanie S, Nishimura T, Chikamoto J, Nagayama S
J Pharm Pharmacol
. 2009 Dec;
61(12):1643-51.
PMID: 19958587
Objectives: The anti-tumour agent S-1 comprises tegafur (a prodrug of 5-fluorouracil; 5-FU), gimeracil (2-chloro-2,4-dihydroxypyridine (CDHP); a competitive inhibitor of 5-FU metabolism) and oteracil potassium. The effect of hepatic dysfunction induced...
5.
Kitamura R, Matsuoka K, Nagayama S, Otagiri M
Drug Metab Pharmacokinet
. 2009 Jan;
23(6):421-7.
PMID: 19122336
The anti-angiogenic agent TSU-68 is known to rapidly induce cytochrome P450 activity responsible for its own hydroxylation in rats. In this study, we identified CYP1A1 and CYP1A2 as the TSU-68-induced...
6.
Fukui Y, Oka T, Nagayama S, Danenberg P, Danenberg K, Fukushima M
Int J Mol Med
. 2008 Nov;
22(6):709-16.
PMID: 19020767
It has been reported that the expression of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phosphoribosyltransferase (OPRT) may predict the clinical efficacy of 5-fluorouracil (5-FU)-based therapy in cancer patients....
7.
Kitamura R, Asanoma H, Nagayama S, Otagiri M
Drug Metab Dispos
. 2008 Mar;
36(6):1003-9.
PMID: 18322074
(Z)-5-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68) is a new anticancer drug that inhibits angiogenic receptor tyrosine kinases, which play a crucial role in tumor-induced vascularization. TSU-68 undergoes hepatic oxidation and glucuronidation. Incubation of...
8.
Kitamura R, Yamamoto Y, Nagayama S, Otagiri M
Drug Metab Dispos
. 2007 Jun;
35(9):1611-6.
PMID: 17567729
TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) is a new drug under investigation that inhibits receptor tyrosine kinases involved in tumor angiogenesis. In clinical pharmacokinetic studies, lower plasma concentrations of orally administered TSU-68 are...
9.
Yamaya H, Saeki M, Yoshida K, Shibata J, Yano S, Sato Y, et al.
Drug Metab Dispos
. 2005 Nov;
34(2):331-8.
PMID: 16299166
(7Alpha)-21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate (TAS-108) is a novel steroidal antiestrogen, modulating the differential recruitment of transcriptional cofactors by liganded estrogen receptors and representing a promising agent for the treatment of breast cancer....
10.
Iwasaki M, Yoshimura Y, Asahi S, Saito K, Sakai S, Morita S, et al.
Drug Metab Pharmacokinet
. 2005 Feb;
19(6):444-52.
PMID: 15681899
As a part of the studies conducted by the Pharma SNPs Consortium (PSC), the enzyme activities of CYP1A2, CYP2A6 and CYP2B6 variants with altered amino acids as a result of...